Physician profile
Brian E Pratt
NPI 1679861256
$29,603.94
in general payments reported to CMS, 2019-2025
43 companies · $20K in 2025
The $20K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.02 · 2020: $297 · 2021: $1,136 · 2022: $1,709 · 2023: $1,328 · 2024: $4,866 · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Consulting Fee: $5,475 · Food and Beverage: $4,645 · Travel and Lodging: $2,358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,923.00 |
| Consulting Fee | $5,475.00 |
| Food and Beverage | $4,644.54 |
| Travel and Lodging | $2,357.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $9,814.35 | 2024-2025 | Sublocade |
| Abbvie INC. | $9,445.40 | 2021-2025 | |
| Eli Lilly and Company | $5,475.00 | 2025 | |
| Novo Nordisk INC | $1,009.00 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $577.46 | 2021-2025 | |
| Lilly USA, LLC | $562.44 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $246.62 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $236.20 | 2020-2024 | Farxiga, Airsupra |
| Amgen INC. | $235.80 | 2023-2025 | Repatha, Otezla, Prolia |
| Pfizer INC. | $220.51 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.20 | 2019-2025 | Jardiance |
| Abbott Laboratories | $118.40 | 2022-2025 | Freestyle Libre 3 |
| Vanda Pharmaceuticals INC. | $117.70 | 2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $115.83 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $115.14 | 2022-2025 | Caplyta |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $114.59 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Xeris Pharmaceuticals, INC. | $109.23 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $90.07 | 2021-2022 | |
| Braeburn INC. | $80.81 | 2024-2025 | Brixadi |
| Janssen Pharmaceuticals, INC | $65.11 | 2020-2021 | |
| Gilead Sciences, INC. | $63.77 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $56.28 | 2023-2024 | Rexulti |
| Mylan Specialty L.P. | $52.91 | 2021 | |
| Nestle Healthcare Nutrition INC. | $45.39 | 2021 | |
| Sanofi Pasteur INC. | $42.98 | 2022-2023 | |
| Dexcom, INC. | $40.96 | 2022-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $39.48 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Daiichi Sankyo INC. | $37.33 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $35.42 | 2021 | |
| Esperion Therapeutics, INC. | $32.80 | 2022-2024 | Nexletol |
| Athena Bioscience, LLC | $28.72 | 2023-2025 | Nexiclon Xr |
| Supernus Pharmaceuticals, INC. | $28.04 | 2023 | Qelbree |
| Lundbeck LLC | $24.79 | 2022 | |
| Linus Health, INC. | $24.38 | 2023 | |
| Axsome Therapeutics, INC. | $21.28 | 2025 | Auvelity |
| Alkermes, INC. | $20.99 | 2024 | Vivitrol |
| Shire North American Group INC | $18.66 | 2019 | |
| Seqirus USA INC | $18.36 | 2022 | |
| Idorsia Pharmaceuticals US INC | $17.76 | 2023 | Quviviq |
| Genentech USA, INC. | $16.00 | 2021 | |
| Aroa Biosurgery Incorporated | $13.75 | 2019 | |
| Corium, LLC | $12.82 | 2023 | Azstarys |
| Boston Scientific Corporation | $12.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Pratt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.